Enhanced CAR T-cell therapy may improve treatment options for patients with B-cell blood cancers
Results from a phase I clinical trial led by The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) show a possible way to improve therapy options for patients with relapsed or treatment-resistant B-cell blood cancers.
Read original article on The Medical News →Related news
-
Congo's confirmed Ebola cases exceed 9,000 as containment efforts falter
United Kingdom
-
Vaccine redesign may separate Zika protection from risk of worsening dengue
United Kingdom
-
Stress during pregnancy may change placental signals linked to fetal brain development
United Kingdom
-
Australian data reveal sharp rise in recorded violence against children over past decade
United Kingdom
-
Pancreatic cancer cells continuously reshape DNA to evade treatment
United Kingdom
-
WHO experts recommend HPV shot for girls aged 4–8
United Kingdom
-
Protein clues may help explain heart disease risk that persists despite lower LDL cholesterol
United Kingdom
-
GLP-1 treatment linked to lower risk of hospitalization and death in older adults with fatty liver disease
United Kingdom